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A self-retaining retractor for the maze procedure
A. Marc Gillinov, MD, Cleveland, Ohio
Most surgical approaches for cure of atrial fibrillationrequire exposure of the pulmonary vein orificesand the posterior left atrium. Visualization of theleft pulmonary veins and posterior left atrium is
challenging, particularly in patients with left atrial enlargement.
The maze procedure includes incisions that isolate the pulmonary
veins, excise the left atrial appendage, and connect the pulmonary
vein encircling incision to the mitral annulus.1 Recent modifica-
tions of the maze procedure recreate some or all of these lesions by
using alternative energy sources that include microwave, radiofre-
quency, cryothermy, and laser sources.2,3 A new set of specially
designed atrial retractor blades that affix to a standard sternal
retractor attachment4 was designed to expose the pulmonary vein
orifices and the posterior left atrium (Kapp Surgical, Cleveland,
Ohio, and Medtronic, Inc, Minneapolis, Minn).
Technique
After median sternotomy, the patient is started on cardiopulmonary
bypass, and the heart is arrested with cold blood cardioplegia. A
standard lateral left atriotomy is constructed after dissection of the
interatrial groove. The posterior left atrium is exposed by means of
placement of 2 retractor blades that are affixed to the bar of a
standard self-retaining mitral valve retractor (Figure 1).
The deeper blade is placed such that its leading edge is adjacent
to the posterior mitral annulus; the blade is malleable and can be
bent to obtain optimal exposure. This blade distracts the mitral
valve toward the patient’s left, thereby exposing the orifices of the
left pulmonary veins (Figure 2). A shorter angled blade is then
positioned cephalad to the first blade. This blade retracts the
superior portion of the left atrium, exposing the left superior
pulmonary vein and the left atrial appendage. In a particularly
large left atrium, the superior blade can be placed over the orifice
of the left atrial appendage to expose the orifice of the left superior
pulmonary vein. The left atrial portion of the operation is then
completed.
From April 2002 through August 2002, this retractor system
was used to perform 35 operations to treat atrial fibrillation. The
From the Department of Thoracic and Cardiovascular Surgery, The Cleve-
land Clinic Foundation, Cleveland, Ohio.
The Cleveland Clinic Foundation has entered into a licensing agreement
with Kapp Surgical, Inc.
Received for publication Sept 17, 2002; accepted for publication Sept 24,
2002.
Address for reprints: A. Marc Gillinov, MD, Department of Thoracic and
Cardiovascular Surgery, The Cleveland Clinic Foundation/F25, 9500 Eu-
clid Ave, Cleveland, OH 44195 (E-mail: gillinom@ccf.org).
J Thorac Cardiovasc Surg 2003;126:287-9
Copyright © 2003 by The American Association for Thoracic Surgery
0022-5223/2003 $30.00  0
doi:10.1016/S0022-5223(02)73612-X
Figure 2. A malleable retractor blade distracts the mitral valve
toward the patient’s left, thereby exposing the left pulmonary
vein orifices. A second shorter blade retracts the superior
portion of the left atriotomy, improving exposure of the left
superior pulmonary vein and the left atrial appendage. Re-
printed with the permission of The Cleveland Clinic Foundation.
Figure 1. The left atrial blades affix to a standard sternal retractor
attachment used for mitral valve surgery. Reprinted with the
permission of The Cleveland Clinic Foundation.
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malleable blades were easily adjusted to accommodate variability
in left atrial size and orientation of the pulmonary veins.
Comment
Development of new operative procedures has caused a resurgence
in the surgical treatment of atrial fibrillation. Like the Cox maze
procedure, these new operations generally include isolation of the
pulmonary veins and excision of the left atrial appendage. Expo-
sure of these structures, particularly in a large left atrium, is
challenging.
A series of new atrial retractor blades (Kapp Surgical Inc,
Cleveland, Ohio) provides exposure of the posterior left atrium and
pulmonary vein orifices. These blades, which are malleable and
universally adjustable, attach to a standard mitral valve retractor.
This system provides excellent and consistent exposure of the
posterior left atrium and pulmonary veins without the need for
surgical assistance, facilitating operations for atrial fibrillation.
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Clopidogrel before urgent coronary artery bypass graft
Michele Genoni, MD,a Reza Tavakoli, MD,a Christoph Hofer, MD,b Osmund Bertel, MD,c and Marko Turina, MD,a
Zurich, Switzerland
The use of platelet aggregation agents, such as aspirin,glycoprotein IIb and IIIa inhibitors, and clopidogrel, hasincreased in recent years for patients with acute coro-nary syndromes, not least because of the results of the
Clopidogrel in Unstable Angina to Prevent Recurrent Events
study.1 In that study, clopidogrel significantly reduced the risk of
cardiovascular death, myocardial infarction, strokes, and other
related ischemic events in patients with acute coronary syndromes.
Clopidogrel demonstrated benefits that were incremental to and
independent of other therapies that the patients might have re-
ceived, such as anticoagulants, angiotensin-converting enzyme
inhibitors, -blockers, and lipid-lowering agents. The study also
confirmed the synergistic effect of the modes of action of clopi-
dogrel and aspirin; clopidogrel inhibits adenosine 5'-diphosphate–
induced platelet aggregation, whereas aspirin inhibits cyclooxy-
genase and reduces thromboxane A2. The obvious inference from
these findings is that all patients with an acute coronary syndrome
should benefit from the favorable effects of clopidogrel, without
exception and without delay, if possible in the prehospital period.
In this case, patients who have not had the opportunity to undergo
coronary angiography with subsequent PCI and who are dependent
on thrombolytic therapy, as well as those who require an urgent
surgical revascularization, would also be treated with clopidogrel.
This raises the question of indications and appropriateness of
clopidogrel administration during the immediate preoperative
course.
Clinical Summary
During a 12-month period (February 2001–January 2002), we
performed 268 isolated coronary artery bypass grafts at our insti-
tution. For patients receiving clopidogrel medication, elective sur-
gery was postponed at least 10 days after stopping clopidogrel. Of
the 268 patients, however, 13 (4.8%) (8 men, 5 women, mean age
68 years) required urgent operation after clopidogrel administra-
tion. All patients had an acute coronary syndrome and had received
clopidogrel already before hospitalization (before coronary an-
giography). In 6 patients (group A), coronary artery bypass graft-
ing was performed within 24 hours of hospitalization because of
hemodynamic instability or critical coronary anatomy. These pa-
tients all received an intra-aortic balloon pump, a -blocker, aspi-
rin, and heparin. The remaining patients (group B) were operated
after at least 7 days of clopidogrel. During this time they received
aspirin, heparin, and a -blocker, as well as initial treatment with
glycoprotein IIb and IIIa inhibitor, but no clopidogrel. Of the 13
operations, 11 were performed without extracorporeal circulation.
There were no deaths in this small series. However, there was a
statistically significant difference between the two groups with
respect to the need for transfusions of packed red blood cells,
fresh-frozen plasma, and platelets (Table 1). In addition, 2 of the
6 patients who were operated on while receiving clopidogrel
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